# Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination

> **NCT02426983** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Ottawa** · enrollment: 12 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DEVICE:** Direct Current Stimulation
- **DRUG:** Dextromethorphan

## Key facts

- **NCT ID:** NCT02426983
- **Lead sponsor:** University of Ottawa
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2015-09
- **Final completion:** 2016-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2015-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426983, "Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02426983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*